Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Accelerate Diagnostics

Accelerate Diagnostics

Jan 16, 2020

JP Morgan Healthcare Day 3: Exact Sciences, NanoString, Natera, Horizon, Accelerate Dx, GenMark, More

Exact Sciences CEO Kevin Conroy discussed the firm's pipeline and plans for 2020 and beyond, while NanoString CEO Brad Gray talked about the company's GeoMx digital spatial profiling technology, among other presentations Wednesday.

Jan 13, 2020

Accelerate Diagnostics Preliminary Q4 Revenues Rise 94 Percent

The firm cited continued delays in getting instruments set up and running in labs, leading to less generation of consumables revenues.

Nov 08, 2019

People in the News: Roland Diggelmann, Victor Esch, Scott Hutton, David Brunel, More

Sep 27, 2019

Accelerate Diagnostics Banking on New Outcomes Data, Experienced COO to Drive Sales Growth

Premium

New outcomes data shows that the firm's test can help clinicians optimize antibiotic prescribing, but investment analysts have had mixed reactions.

Sep 27, 2019

Luminex, Accelerate Diagnostics Downgraded by JP Morgan to Underweight

The investment bank adjusted its December 2020 price target for Luminex's stock to $21 and for Accelerate Diagnostics' stock to $16.

Dec 26, 2018

GenMark Fungal Blood Culture Test Clears FDA

The test is the second of three panels intended to detect pathogens that cause the bloodstream infections that can lead to sepsis.

Aug 23, 2018

Luminex Verigene MDx Panel Speeds Up AST, Reduces Cost, Study Finds

Premium

Clinicians identifying and treating S. aureus bloodstream infections reduced the median length of stay by 5.6 days and hospital cost by $13,341 per patient after using Luminex's assay.

Jun 15, 2017

FDA Clearance for GenMark's ePlex Intensifies Competition in Highly Plexed MDx Test Market

Premium

The firm will encounter stiff competition, particularly from BioMérieux and Luminex, but there are untapped opportunities for adoption, according to industry analysts.

Sep 16, 2016

Sepset Biosciences Developing Sepsis Test Based on Cellular Reprogramming Signature

Premium

The test is based on a biomarker signature that consists of a core set of 31 genes associated with endotoxin tolerance in sepsis patients.

Jul 22, 2016

Speed and Accuracy Top Considerations for Lab Directors in Choosing Sepsis Dx

Premium

Despite the array of tests available, some lab directors are still seeking broader functionalities and capabilities from the systems they purchase.  

Pages

The Scan

Shift to New Variant Work

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

Victim Identified with Genetic Genealogy

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

PNAS Papers on Chemotherapy-Induced Cardiac Injury Target, Viral Insertions, SMRT Methylation Profiling

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Should Also Work

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.